[{"id":"d479d7a5-69ba-49e5-93fa-ae230286eb90","acronym":"CL1-95029-001","url":"https://clinicaltrials.gov/study/NCT05162755","created_at":"2021-12-17T17:31:24.245Z","updated_at":"2025-02-25T14:02:39.100Z","phase":"Phase 1","brief_title":"S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers","source_id_and_acronym":"NCT05162755 - CL1-95029-001","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" HER-2 • KRAS • BRAF • NRAS","pipe":" | ","alterations":" BRAF V600E • KRAS wild-type","tags":["HER-2 • KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e futuximab/modotuximab (S95026) • S95029 • Sym021"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 10/15/2021","start_date":" 10/15/2021","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 06/19/2025","study_completion_date":" 06/19/2025","last_update_posted":"2025-02-19"},{"id":"71b6e7a1-e8f9-4246-9907-95c8f1bd4257","acronym":"","url":"https://clinicaltrials.gov/study/NCT06162572","created_at":"2023-12-08T19:16:46.816Z","updated_at":"2025-02-25T14:42:34.136Z","phase":"Phase 1/2","brief_title":"Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT06162572","lead_sponsor":"Servier Bio-Innovation LLC","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • S95018 • S95029"],"overall_status":"Recruiting","enrollment":" Enrollment 176","initiation":"Initiation: 08/07/2024","start_date":" 08/07/2024","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2025-02-14"},{"id":"a97f479a-477d-44f3-a5e0-9f9fc842a61b","acronym":"Keynote E70","url":"https://clinicaltrials.gov/study/NCT06116136","created_at":"2023-11-03T20:12:25.319Z","updated_at":"2025-02-25T14:42:27.915Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.","source_id_and_acronym":"NCT06116136 - Keynote E70","lead_sponsor":"Servier Bio-Innovation LLC","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • S95029"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 08/31/2024","start_date":" 08/31/2024","primary_txt":" Primary completion: 06/10/2026","primary_completion_date":" 06/10/2026","study_txt":" Completion: 06/01/2029","study_completion_date":" 06/01/2029","last_update_posted":"2025-02-14"}]